Evaluation of Critical Formulation Factors in the Development of a Rapidly Dispersing Captopril Oral Dosage Form

Drug Development and Industrial Pharmacy

Volumn 29, Issue 9, 2003, Pages 967-979

  Lee, Kyoung Jin ^a   Kang, Anthony ^b   Delfino, John J ^b   West, Thomas G ^b   Chetty, Dushen ^c   Monkhouse, Donald C ^b   Yoo, Jaedeok ^b  

^a Locus Discovery Inc   (United States)

^b Therics Inc   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

3DP; Captopril; Experimental design; Fast dissolve; Hypertensive emergency; Maltitol; Maltodextrin; Mannitol; Polyvinyl pyrrolidone; Quick dissolve; Rapid prototyping; Rapidly dispersing tablet; Solid freeform fabrication; TheriForm process

Indexed keywords

ASCORBIC ACID; CAPTOPRIL; EDETIC ACID; EXCIPIENT; MALTITOL; MALTODEXTRIN; MANNITOL; POVIDONE;

ARTICLE; CHEMISTRY; DRUG DOSAGE FORM; DRUG FORMULATION; EXPERIMENTAL DESIGN; HARDNESS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; INSTRUMENTATION; METHODOLOGY; MOISTURE; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; REGRESSION ANALYSIS; SYNTHESIS;

ADMINISTRATION, ORAL; CAPTOPRIL; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0242290012     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-120025454     Document Type: Article

References (34)

1. Seager, H. Drug delivery products and the Zydis fast dissolving dosage form. J. Pharm. Pharmacol 1998, 50 (4), 375-382.
2. Johannessen, T.; Kristensen, P. On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast dissolving famotidine wafers and ranitidine tablets. Clin. Ther. 1997, 19 (1), 73-81.
3. The fifth report of the joint national committee on detection, evaluation, and treatment of high hlood pressure (JNC V). Arch. Intern. Med. 1993, 153 (2), 154-183.
4. Nur, A.O.; Zhang, J.S. Recent progress in sustained/controlled oral delivery of captopril: an overview. Int. J. Pharm. 2000, 194 (2), 139-146.
5. Ohman, K.P.; Kagedal, B.; Larsson, R.; Kalberg, E.B. Pharmacokinetics of captopril and its effect on blood pressure during acute and chronic administration and in relation to food intake. J. Cardiovasc. Pharm. 1985, 7, S20-S24.
6. Ceyhan, B.; Karaaslan, Y.; Caymaz, O.; Oto, A.; Oram, E.; Oram, A.; Ugurlu, S. Comparison of sublingual captopril and sublingual nifedifine in hypertensive emergencies. Jpn. J. Pharmacol. 1990, 52, 189-193.
7. Angeli, P.; Chiesa, M.; Caregaro, L.; Merkel, C.; Sacerdoti, D.; Rondana, M.; Gatta, A. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. Arch. Intern. Med. 1991, 151, 678-682.
8. Karachalios, G.N.; Chrioskos, N.; Kintziou, H.; Perogianopouos, K.; Kehagioglow, K. Treatment of hypertensive crisis with sublingual captopril. Curr. Ther. Res. 1990, 48 (1), 5-9.
9. Haude, M.; Steffen, W.; Erbel, R.; Meyer, J. Sublingual administration of captopril versus nitroglycerin in patients with severe heart failure. Int. J. Cardiology 1990, 27, 351-359.
10. Al-Furaih, T.A.; McElnay, J.C.; Elborn, J.S.; Rusk, R.; Scott, M.G.; McMahon, J.; Nicholls, D.P. Sublingual captopril-a pharmacokinetic and pharmacodynamic evaluation. Eur. J. Clin. Pharmacol. 1991, 40, 393-398.
11. McElnay, J.C.; Al-Furaih, T.A.; Hughes, C.M.; Scott, M.G.; Nicholls, D.P. A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure. Eur. J. Clin. Pharmacol. 1996, 49 (6), 471-476.
12. Kearney, P.; Wong, S.K. Method for Making Freeze Dried Drug Dosage Forms. US Patent 5,631,023, May 20, 1997.
13. Green, R.; Kearney, P. Process for Preparing Fast Dispersing Solid Oral Dosage Form. US Patent 5,976,577, November 2, 1999.
14. Mizumoto, T.; Masuda, Y.; Fukui, M. Intrabuccally Dissolving Compressed Moldings and Production Process Thereof. US Patent 5,576,014, November 19, 1996.
15. Dijkgraaf, B.L.J.; Muhlenbruch, A. Granulate for the Preparation of Fast-Disintegrating and Fast-Dissolving Compositions Containing A High Amount of Drug. US Patent 5,837,292, November 17, 1998.
16. Khankari, R.K.; Hontz, J.; Chastain, S.J.; Katzner, L. Rapidly Dissolving Robust Dosage Form. US Patent 6,024,981, February 15, 2000.
17. Pather, S.I.; Robinson, J.R.; Eichman, J.D.; Khankari, R.K.; Hontz, J.; Gupte, S.V. Effervescent Drug Delivery System for Oral Administration. US Patent 6,391,335, May 21, 2002.
18. Fuisz, R.C. Rapidly Dispersible Compositions Containing Polydextrose. US Patent 5,501,858, March 26, 1996.
19. Myers, G.L.; Battist, G.E.; Fuisz, R.C. Process and Apparatus for Making Rapidly Dissolving Dosage Units and Product Therefrom. US Patent 5,866,163, February 2, 1999.
20. Sachs, E.M.; Haggerty, J.S.; Cima, M.J.; Williams, P.A. Three-Dimensional Printing Techniques. US Patent 5,204,055, April 20, 1993.
21. Cima, M.J.; Sachs, E.; Cima, L.G.; Yoo, J.; Khanuja, S.; Borland, S.W.; Wu, B.; Giordano, R.A. Computer-derived microstructures by 3D printing: Bio- and Structural Materials. Solid Freeform Fabrication Symposium Proceedings, Univ. of Texas, 1994; 181-190.
22. Wu, B.M.; Borland, S.W.; Giordano, R.A.; Cima, L.G.; Sachs, E.M.; Cima, M.J. Solid free-form fabrication of drug delivery devices. J. Control. Release 1996, 40, 77-87.
23. Katstra, W.E.; Palazzolo, R.D.; Rowe, C.W.; Giritlioglu, B.; Teung, P.; Cima, M.J. Oral dosage forms fabricated by three dimensional printing. J. Control. Release 2000, 66 (1), 1-9.
24. Rowe, C.W.; Katstra, W.E.; Palazzolo, R.D.; Giritlioglu, B.; Teung, P.; Cima, M.J. Multimechanism oral dosage forms fabricated by three dimensional printing. J. Control. Release 2000, 66 (1), 11-17.
25. Lin, S.; Chao, P.; Chien, Y.W.; Sayani, A.; Kumar, S.; Mason, M.; West, T.; Yang, A.; Monkhouse, D.C. In vitro and in vivo evaluations of biodegradable implants for hormone replacement therapy: effect of system design and PK-PD relationship. AAPS Pharm. Sci. Tech. 2001, 2 (3), Article 16.
26. Yoo, J.; Kumar, S.; Rowe, C.W.; Monkhouse, D.C.; Shanahan, G.; Kang, A. Factors influencing the dispersion of rapidly dissolving oral dosage forms fabricated by the TheriForm™ process. AAPS Pharm. Sci. 1999, 1 (1); 1998 AAPS Annual Meeting Supplement.
27. Rowe, C.W.; Wang, C.; Monkhouse, D. TheriForm™ technology. Modified-Release Drug Delivery Technology; Rathbone, M.J., Hadgraft, J., Roberts, M.S., Eds.; Marcel Dekker, Inc., 2002; 77-87.
28. Yoo, J.; Kumar, S.; Monkhouse, D. Dosage Form Exhibiting Rapid Disperse Properties, Methods of Use and Process for the Manufacture of Same. US Patent 6,471,992, October 29, 2002.
29. Pereira, C.M.; Tam, Y.K. Simplified determination of captopril in plasma by high performance liquid chromatography. J. Chromatogr. 1988, 425, 208-213.
30. Tsai, T.; San, Y.P.; Ho, H.S.; Wu, J.S.; Sheu, M.T. Film-forming polymer-granulated excipients as the matrix materials for controlled release dosage form. J. Control. Release 1998, 51 (2-3), 289-299.
31. Draper, N.R.; Smith, H. Selecting the best regression equation. Applied Regression Analysis, 2nd Ed.; Wiley: New York, 1981; 225-311.
32. Seta, Y.; Higuchi, F.; Kawahar, Y.; Nishimura, K.; Okada, R. Design and preparation of captopril sustained-release dosage forms and their biopharmaceutical properties. Int. J. Pharm. 1988, 29, 245-254.
33. Allen, L.V.; Erickson, M.A. Stability of baclofen, captopril, diltiazem hydrochloride, dipyramide, and flecainide acetate in extemporaneously compounded oral liquids. Am. J. Health-Syst. Ph. 1996, 53 (18), 2179-2184.
34. Yoo, J. Comprehensive report on the development and process scale up of pseudoephedrine HCl TheriFlash™ dosage form. Internal Communications, Theries, Inc., 1999; On file.